| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.07 | 0.2 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.2 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |